Home clinical
 

Keywords :   


Tag: clinical

Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016

2016-10-03 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the companys chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Mercks HCV clinical development programs. Language: English Contact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the data development present

 

Remedy Pharmaceuticals Announces Contest To Name Its Subarachnoid Hemorrhage Clinical Trial

2016-06-08 04:14:03| drugdiscoveryonline News Articles

Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, recently announced a contest to name its upcoming clinical trial in Subarachnoid Hemorrhage (SAH)

Tags: trial clinical contest announces

 
 

Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial

2016-06-01 04:49:19| drugdiscoveryonline Home Page

Syros Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, into a Phase 2 clinical trial in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS) identified through its platform

Tags: trial advance phase acceptance

 

Grafix Demonstrates Superior Clinical Outcomes Compared With EpiFix In Real World' Study

2016-05-03 03:28:13| drugdiscoveryonline News Articles

Osiris Therapeutics, Inc., a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix versus EpiFix

Tags: real world study compared

 

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

2016-03-30 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Presentations Include Results from Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the companys broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: international development present programs

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »